Home › Non-Small Cell Lung Cancer › Colorado
Non-Small Cell Lung Cancer clinical trials in Colorado
73 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Colorado.
Cities in Colorado
- Aurora30 studies
- Denver27 studies
- Centennial15 studies
- Colorado Springs11 studies
- Grand Junction8 studies
- Arvada7 studies
- Highlands Ranch6 studies
- Boulder6 studies
- Fort Collins6 studies
- Loveland5 studies
- Greeley5 studies
- Thornton4 studies
- Westminster3 studies
- Pueblo3 studies
- Lakewood3 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Rocky Mountain Cancer Centers-Aurora, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Rocky Mountain Cancer Centers-Boulder, Boulder
- and 13 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- University of Colorado Anschutz Medical Campus ( Site 0151), Aurora
- UCHealth Memorial Hospital Central ( Site 0125), Colorado Springs
- Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207), Greeley
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Lutheran Medical Center - Cancer Centers of Colorado, Wheat Ridge
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- AdventHealth Parker, Parker
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Rocky Mountain Cancer Center, Denver
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute at HealthOne, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Rocky Mountain Cancer Centers, LLP, Pueblo
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07365319Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #87, Littleton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- University of Colorado Cancer Center ( Site 3268), Aurora
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07513376Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Kaiser Permanente-Franklin, Denver
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
- Kaiser Permanente-Rock Creek, Lafayette
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Intermountain Health Cancer Center Lutheran Hospital, Golden
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0340, Lakewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Rocky Mountain Cancer Centers, Boulder
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- University Of Colorado - Anschutz Medical Campus /ID# 269069, Aurora
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603, Lone Tree
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Rocky Mountain Cancer Centers LLP, Aurora
- Rocky Mountain Cancer Centers LLP, Boulder
- Rocky Mountain Cancer Centers LLP, Centennial
- and 11 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Intermountain Health Cancer Center Lutheran Hospital, Golden
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Intermountain Health St. Mary's Regional Hospital, Grand Junction
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Rocky Mountain Cancer Centers, Lone Tree
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132), Grand Junction
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06170788Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Rocky Mountain Cancer Centers,LLP, Aurora
- Rocky Mountain Cancer Centers,LLP, Denver
- Rocky Mountain Cancer Centers,LLP, Lone Tree
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07227298Pan-tumor MRD Study
- The Melanoma and Skin Cancer Institute, Englewood
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0500, Grand Junction
- Local Institution - 0472, Westminster
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Vail Health Hospital - Shaw Cancer Center, Edwards
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07140016Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Vail Health, Vail
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Colorado Cancer Center, Aurora
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Shaw Cancer Center, Edwards
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- National Jewish Health Medical Center, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06875310Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Colorado Cancer Center, Aurora
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- SCRI at HCA HealthONE, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07705334Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Aurora
- Clinical Study Site, Denver
- Clinical Study Site, Grand Junction
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- University of Colorado - Aurora Cancer Center, Aurora
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-872-H, Aurora
- Local Institution - 007-872-D, Boulder
- Local Institution - 007-872-L, Centennial
- and 10 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04613596Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- Rocky Mountain Cancer Centers, Lone Tree
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04486833ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Colorado, Aurora
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06914128A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Colorado Cancer Center, Aurora
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- UC Health Oncology Research, Colorado Springs
- Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System, Fort Collins
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Rocky Mountain Cancer Centers, Lone Tree
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- University of Colorado Health Hospital, Aurora
- Sarah Cannon Research Institute at HealthOne, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06561685Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Grand Junction
- Research Site, Wheat Ridge
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07291037Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- University of Colorado Cancer Center, Aurora
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06343402From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.